DepoVax Technology Selected for HPV–related Cancer Trials - - BioPharm International

ADVERTISEMENT

DepoVax Technology Selected for HPV–related Cancer Trials



Dana-Farber has been awarded a research grant of $1.2 million for clinical evaluation of its cancer vaccine. The grant from Stand Up To Cancer and the Farrah Fawcett Foundation was awarded to a team of Dana-Farber researchers at the 2014 American Association for Cancer Research annual meeting. The three-year grant will be used to fund a Phase I clinical trial of the group’s peptide cancer antigen formulated in DepoVax in patients with HPV-related cervical, head, and neck cancers.

The grant was awarded based on a proposal highlighting the potential of Dana-Farber’s proposed cancer antigen identified by a new mass spectrometry method termed Poisson detection MS and Immunovaccine’s DepoVax platform. The DepoVax data focused on clinical trial results with DPX-Survivac, which demonstrated strong immune response activity in cancer patients and the immune enhancement observed with the immune modulating agent cyclophosphamide. Dana-Farber’s proposed Phase I study in HPV-related cancers will use the same approach, formulating the Institute'speptide-based vaccine in DepoVax and administering it to patients in combination with cyclophosphamide.

Source: Immunovaccine
blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines

Click here